1. IAPAC-Lancet HIV Commission on the future of urban HIV responses.
- Author
-
Zuniga JM, Prachniak C, Policek N, Magula N, Gandhi A, Anderson J, Diallo DD, Lima VD, Ravishankar S, Acharya S, Achrekar A, Adeleke M, Aïna É, Baptiste S, Barrow G, Begovac J, Bukusi E, Castel A, Castellanos E, Cestou J, Chirambo G, Crowley J, Dedes N, Ditiu L, Doherty M, Duncombe C, Durán A, Futterman D, Hader S, Kounkeu C, Lawless F, Lazarus JV, Lex S, Lobos C, Mayer K, Mejia M, Moheno HR, d'Arminio Monforte A, Morán-Arribas M, Nagel D, Ndugwa R, Ngunu C, Poonkasetwattana M, Prins M, Quesada A, Rudnieva O, Ruth S, Saavedra J, Toma L, Wanjiku Njenga L, and Williams B
- Subjects
- Humans, Urban Population, HIV Infections epidemiology, HIV Infections prevention & control
- Abstract
Competing Interests: Declaration of interests JMZ has received consulting fees from Gilead Sciences and Merck & Co. JA has received consulting fees from Gilead Sciences; honoraria from Gilead Sciences and ViiV Healthcare; travel support from Gilead Sciences and ViiV Healthcare; book royalties from Elsevier Royalties; and has served on a Data Safety and Monitoring Board for the RIO HIV Trial. DDD has received consulting fees from Gilead Sciences and honoraria from Gilead Sciences and ViiV Healthcare. VDL has received research grants from the Canadian Foundation for AIDS Research and Canadian Institutes of Health Research and an honorarium from ViiV Healthcare. AC has received a research grant from Gilead Sciences. ND has received an honorarium from ViiV Healthcare. CD has received consulting fees from WHO. SH has received consulting fees from the BCG Boston Consulting Group. JVL has received consulting fees from Echosens, GlaxoSmithKline, Novo Nordisk, NovoVax, and Pfizer; honoraria from AbbVie, Echosens, Gilead Sciences, Janssen Therapeutics, Moderna, Merck Sharp & Dohme, Novo Nordisk, Pfizer; and has served on a Data Safety and Monitoring Board for the QuickStart Study. KM has received research grants and consulting fees from Gilead Sciences, Merck & Co, and ViiV Healthcare. MM has received consulting fees from Janssen Therapeutics. SRa has received an honorarium from the AIDS Healthcare Foundation. All other authors declare no competing interests.
- Published
- 2024
- Full Text
- View/download PDF